Dr Emmanuel Antonarakis speaks to ecancer about his ASCO 2020 Virtual meeting presentation on the types of BRCA mutations and their association with response to PARP inhibitors.
He notes that the presentation is very topical due to the recent FDA approvals of olaparib and rucaparib for prostate cancer. Patients in the study were given one of these two drugs.
Dr Antonarakis explains the data appears to suggest that BRCA1/2 homozygous deletion mutations are correlated with the best outcomes to PARP inhibitor therapy. He notes that this data is from a small population and requires further research, outlining some potential study designs.
This programme has been supported by an unrestricted educational grant from Pfizer.